It is currently Sat Apr 18, 2015 4:41 pm

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Higher dose of Copaxone in clinical trials

I guess it's good news, just not as exciting as a treatment that might actually be a breakthrough. I'm not complaining though...and now there's something new to add to the phase III section of the list.



Teva Announces That Higher Dose of Copaxone Showed Increased Efficacy in Multiple Sclerosis (MS)

BUSINESS WIRE - April 5, 2006 - A new, higher dose of Copaxone (glatiramer acetate injection) showed promising results in the treatment of patients with ...
Read more : Higher dose of Copaxone in clinical trials | Views : 1363 | Replies : 0


Avonex plus Doxycycline trial preliminary results

An abstract from the AAN meeting about the combination trial of doxycycline and Avonex. The preliminary, small sample results look promising.



Combination Therapy with Intramuscular Interferon Beta-1a and Oral Doxycycline in Patients with Multiple Sclerosis: An Open-Label Trial

Alireza Minagar, J. Steven Alexander, Rhonda Brooks, Roger E. Kelley, Robert N. Schwendimann, Eduardo Gonzalez-Toledo, Dana Merrill Bryan, Shreveport, LA

OBJECTIVE: To determine the safety, tolerability, and efficacy of doxycycline combined with intramuscular (IM) interferon beta-1a (IFNb-1a) ...
Read more : Avonex plus Doxycycline trial preliminary results | Views : 4883 | Replies : 23


BHT-3009 Meeting/Info Results

There's some great info about the drug below.


Bayhill Therapeutics, Inc. Research on Multiple Sclerosis Chosen as One of the Meeting's Scientific Program Highlights at the 58th Annual Meeting of the American Academy of Neurology
4/4/2006 8:41:00 AM EST

Bayhill Therapeutics will make two presentations today at the 58th Annual Meeting of the American Academy of Neurology in San Diego in connection with development of the company's lead drug candidate, BHT-3009, for the treatment of ...
Read more : BHT-3009 Meeting/Info Results | Views : 1328 | Replies : 0


Better Rebif

A new and improved Rebif. Can't really see if it actually does anything better for the disease.

It's funny that as new therapies are on the horizon that Biogen published info yesterday that Avonex after first CIS substantially delayed dx of MS and now Serono has come up with a better Rebif.

The only interesting part of the article was "Serono also is taking a leading role in developing an understanding of the role of ...
Read more : Better Rebif | Views : 1446 | Replies : 1


KineMed

It might as well be written in Chinese, but it looks as if another company is looking at possbible therapies for MS and other neurological diseases - which must be good.

http://c.moreover.com/click/here.pl?j500810681&w=464753
Read more : KineMed | Views : 1346 | Replies : 1


Completed Phase II trial of oral IFN-alpha

Interesting that this talks about a completed phase II trial of an oral treatment. I hope if they do another trial it will be phase III.



Ingested (oral) IFN-alpha represses TNF-alpha mRNA in relapsing-remitting multiple sclerosis.

J Interferon Cytokine Res. 2006 Mar;26(3):150-5.
Brod SA, Nguyen M, Hood Z, Shipley GL.
Department of Neurology, University of Texas-Houston, Health Science Center (UTHHSC), Houston, TX 77030, USA. staley.a.brod@uth.tmc.edu

In a phase II trial ...
Read more : Completed Phase II trial of oral IFN-alpha | Views : 1645 | Replies : 2


Neurovax news

The additions to the board are impressive e.g Antel and Bourdette. These T-Reg cells keep cropping up and were mentioned in the Zenapax (Dacluzimab) article recently posted.

PS Where has my workmate Dignan gone? Good to see that Dunmann is taking up the slack. This time next week I will be in Mauritius so I'll be expecting Dignan to start getting his hands dirty again.

Ian

Prestigious Board to Guide Research and Development of NeuroVax(TM) ...
Read more : Neurovax news | Views : 1278 | Replies : 0


Tovaxin

The company behind Tovaxin are presenting data at a conference in early May


http://c.moreover.com/click/here.pl?j496703398&w=464753
Read more : Tovaxin | Views : 1250 | Replies : 0


Zenapax (Daclizumab)

Hopes raised for effectiveness of Multiple Sclerosis drug

A national research team led by the University of Cincinnati's Bibiana Bielekova, MD, report new insights into how anti-rejection drug helps MS patients
Discovery of the mechanism of a drug being tested for the treatment of multiple sclerosis (MS) has revealed that it's not only more effective than first thought, but might also help in the management of other autoimmune diseases, organ transplant rejection and even cancer. ...
Read more : Zenapax (Daclizumab) | Views : 2213 | Replies : 7


NNZ-2566

This is one of the drugs in the pipeline at Neuren. It is a neuro-protective drug and pre-clinical results look promising. I think it has just entered into Phase 1 human trials.

See 22 March news on the company's website.

Let's hope that the human trial results are as good

<shortened url>
Read more : NNZ-2566 | Views : 1345 | Replies : 0


 

Login  •  Register


Statistics

Total posts 224764 • Total topics 23503 • Total members 14894


Contact us | Terms of Service